To evaluate Sal B’s therapeutic efficacy against HRD, key biomarkers associated with inflammation and renal injury, including interleukin-6 (IL-6), neutrophil gelatinase-associated lipocalin (NGAL), and transforming growth factor-beta (TGF-β), were quantitatively measured. The gene discussed is LCN2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.